Impact of positive CD4 cells on event-free survival in follicular lymphoma patients

被引：1
作者：
Li, Cong [1 ]
Guo, Na [2 ]
Han, Shuiyun [1 ]
Yu, Haifeng [1 ]
Lei, Tao [1 ]
Chen, Xi [1 ]
Peng, Shuailing [1 ]
Yang, Haiyan [1 ,2 ]
Wu, Meijuan [1 ,2 ]
机构：
[1] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med HIM, Dept Lymphoma, Hangzhou 310022, Zhejiang, Peoples R China
[2] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med HIM, Dept Pathol, Hangzhou 310022, Zhejiang, Peoples R China
来源：
CANCER MEDICINE | 2024年 / 13卷 / 17期
关键词：
CD4+; event-free survival; follicular lymphoma; immunohistochemistry; prognosis; GENE-EXPRESSION; T-CELLS; TUMOR MICROENVIRONMENT; RITUXIMAB; RISK; VALIDATION; PREDICTION;
D O I：
10.1002/cam4.70117
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Objective: Previous results about prognostic value of CD4+ T cells in follicular lymphoma (FL) remain controversial. Methods: Immunohistochemistry was used to examine expression of positive CD4 cells in 103 patients with FL 1-3A. Early failure was described as failing to achieve event-free survival (EFS) at 12 or 24 months. Results: There were 49 (47.6%) male and 54 (52.4%) females, with a median age of 54 years. Compared to patients with <20% of positive CD4 cells, patients with >= 20% of positive CD4 cells exhibited a significant lower risk of early failure (2-year EFS rate: 56.7% vs 73.5%, p = 0.047). When patients were stratified based on positive CD4 cell combined with FLIPI, the median EFS (p = 0.002) and median OS (p = 0.007) were significantly different. Conclusions: This study demonstrated that higher expression of positive CD4 cells predicts lower risk of early failure in follicular lymphoma, and combination analysis of CD4 and FLIPI could better predict disease relapse and survival outcome.
引用
收藏
页数：9
相关论文
共 38 条
  • [1] Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma
    Al-Tourah, Abdulwahab J.
    Gill, Karamjit K.
    Chhanabhai, Mukesh
    Hoskins, Paul J.
    Klasa, Richard J.
    Savage, Kerry J.
    Sehn, Laurie H.
    Shenkier, Tamara N.
    Gascoyne, Randy D.
    Connors, Joseph M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (32) : 5165 - 5169
  • [2] Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients
    Alvaro, Tomas
    Lejeune, Marylene
    Salvado, Maria-Teresa
    Lopez, Carlos
    Jaen, Joaquin
    Bosch, Ramon
    Pons, Lluis E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) : 5350 - 5357
  • [3] Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells
    Ame-Thomas, P.
    Le Priol, J.
    Yssel, H.
    Caron, G.
    Pangault, C.
    Jean, R.
    Martin, N.
    Marafioti, T.
    Gaulard, P.
    Lamy, T.
    Fest, T.
    Semana, G.
    Tarte, K.
    [J]. LEUKEMIA, 2012, 26 (05) : 1053 - 1063
  • [4] Vulnerabilities in the tumor and microenvironment in follicular lymphoma
    Araujo-Ayala, Ferran
    Perez-Galan, Patricia
    Campo, Elias
    [J]. HEMATOLOGICAL ONCOLOGY, 2021, 39 : 83 - 87
  • [5] Rituximab versus a watch-and-wait approach in patients with advanced- stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial
    Ardeshna, Kirit M.
    Qian, Wendi
    Smith, Paul
    Braganca, Nivette
    Lowry, Lisa
    Patrick, Pip
    Warden, June
    Stevens, Lindsey
    Pocock, Christopher F. E.
    Miall, Fiona
    Cunningham, David
    Davies, John
    Jack, Andrew
    Stephens, Richard
    Walewski, Jan
    Ferhanoglu, Burhan
    Bradstock, Ken
    Linch, David C.
    [J]. LANCET ONCOLOGY, 2014, 15 (04) : 424 - 435
  • [6] A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy
    Bachy, Emmanuel
    Maurer, Matthew J.
    Habermann, Thomas M.
    Gelas-Dore, Benedicte
    Maucort-Boulch, Delphine
    Estell, Jane A.
    Van den Neste, Eric
    Bouabdallah, Reda
    Gyan, Emmanuel
    Feldman, Andrew L.
    Bargay, Joan
    Delmer, Alain
    Slager, Susan L.
    da Silva, Maria Gomes
    Fitoussi, Olivier
    Belada, David
    Maisonneuve, Herve
    Intragumtornchai, Tanin
    Ansell, Stephen M.
    Lamy, Thierry
    Dartigues, Peggy
    Link, Brian K.
    Seymour, John F.
    Cerhan, James R.
    Salles, Gilles
    [J]. BLOOD, 2018, 132 (01) : 49 - 58
  • [7] Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe D'Etude des Lymphomes Folliculaires
    Brice, P
    Bastion, Y
    Lepage, E
    Brousse, N
    Haioun, C
    Moreau, P
    Straetmans, N
    Tilly, H
    Tabah, I
    SolalCeligny, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) : 1110 - 1117
  • [8] Follicular lymphoma
    Carbone, Antonino
    Roulland, Sandrine
    Gloghini, Annunziata
    Younes, Anas
    von Keude, Gottfried
    Lopez-Guillermo, Armando
    Fitzgibbons, Jude
    [J]. NATURE REVIEWS DISEASE PRIMERS, 2019, 5 (1)
  • [9] High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma
    Carreras, Joaquim
    Lopez-Guillermo, Armando
    Fox, Bridget C.
    Colomo, Lluis
    Martinez, Antonio
    Roncador, Giovanna
    Montserrat, Emili
    Campo, Elias
    Banham, Alison H.
    [J]. BLOOD, 2006, 108 (09) : 2957 - 2964
  • [10] Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
    Casulo, Carla
    Byrtek, Michelle
    Dawson, Keith L.
    Zhou, Xiaolei
    Farber, Charles M.
    Flowers, Christopher R.
    Hainsworth, John D.
    Maurer, Matthew J.
    Cerhan, James R.
    Link, Brian K.
    Zelenetz, Andrew D.
    Friedberg, Jonathan W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (23) : 2516 - U55
1234